

1/22

Drawings

Fig. 1 lyophilization of forms R, A, O and C in order as depicted from left to right.




Fig. 2 lyophilization of forms G, Q, S and T in order as depicted from left to right.

2/22




Fig. 3 lyophilization of forms U and V in order as depicted from left to right.



XRPD pattern obtained for "Form A 40 pass" lyophilized sample (black trace) and XRPD pattern of CoQ10 bulk drug substance (red trace). The pattern has been normalized so that the intensity of the most intense peak equals 100%.


Fig. 4

3/22



XRPD pattern obtained for "Form C 20 pass" lyophilic sample (black trace) and XRPD pattern of CoQ10 bulk drug substance (red trace). The pattern has been normalized so that the intensity of the most intense peak equals 100%.


Fig. 5



XRPD pattern obtained for "Form G 20 pass" lyophilic sample (black trace) and XRPD pattern of CoQ10 bulk drug substance (red trace). The pattern has been normalized so that the intensity of the most intense peak equals 100%.


Fig. 6

4/22



XRPD pattern obtained for "Form O 20 pass" lyophilic sample (black trace) and XRPD pattern of CoQ10 bulk drug substance (red trace). The pattern has been normalized so that the intensity of the most intense peak equals 100%.


Fig. 7



XRPD pattern obtained for "Form Q 20 pass" lyophilic sample (black trace) and XRPD pattern of CoQ10 bulk drug substance (red trace). The pattern has been normalized so that the intensity of the most intense peak equals 100%.


Fig. 8

5/22



XRPD pattern obtained for "Form 8 20 pass" lyophilic sample (black trace) and XRPD pattern of CoQ10 bulk drug substance (red trace). The pattern has been normalized so that the intensity of the most intense peak equals 100%.


Fig. 9



XRPD pattern obtained for "Form 8 20 pass" lyophilic sample (black trace) and XRPD pattern of CoQ10 bulk drug substance (red trace). The pattern has been normalized so that the intensity of the most intense peak equals 100%.


Fig. 10

6/22



XRPD pattern obtained for "Form T 20 pass" lyophilic sample (black trace) and XRPD pattern of CoQ10 bulk drug substance (red trace). The pattern has been normalized so that the intensity of the most intense peak equals 100%.


Fig. 11



XRPD pattern obtained for "Form U 20 pass" lyophilic sample (black trace) and XRPD pattern of CoQ10 bulk drug substance (red trace). The pattern has been normalized so that the intensity of the most intense peak equals 100%.


Fig. 12

7/22



XRPD pattern obtained for "Form V 20 pass" lyophilic sample (black trace) and XRPD pattern of CoQ10 bulk drug substance (red trace). The pattern has been normalized so that the intensity of the most intense peak equals 100%.

Fig. 13



. Effect of number of passes on particle size.
 5g of Cytotech31510, 3g of DMPC, and 92 ml of water.
 The MFz model – M-110P. Processing chamber – F12Y.
 Maximum pressure – 25,000 PSI.

Fig. 14

8/22




Fig. 15




Fig. 16




Fig. 17

9/22




Fig. 18




Fig. 19

10/22




Fig. 20




Fig. 21

11/22




Fig. 22


Efficacy by treatment group:

Fig. 23

12/22




Efficacy by treatment group:

Fig. 24

No poloxamer

Media
50uMQ10
100uMQ10

With poloxamer

Media
50uMQ10
100uMQ10

Fig. 25 - Effect of IV formulation on OCR in HepG2 cells.

13/22




Fig. 26 - Effect of IV formulations on OCR in MCF-7 cells




Fig. 27 - Effect on IV formulations on OCR in PC-3 cells.




Fig. 28 - Effect of IV formulations on OCR on PaCa2 cells.




Fig. 29




Fig. 30




Fig. 31




Fig. 32




Fig. 33

16/22




Fig. 34




Fig. 35

17/22






Fig. 36



As can be seen, all animals were dead by approximately day 21.


Fig. 37

18/22



As can be seen, the same was observed with the group receiving saline, without a change in survival rates.


Fig. 38



There was a prolongation of life by approximately 15 days by the excipient control. This does not indicate a therapeutic effect per se, rather, a palliative effect parallel to what is observed in humans with life prolongation.


Fig. 39

19/22



At 0.5 mg/kg 31510, there was an increase in survival days by 10 days.

Fig. 40



In this group there was a statistically significant prolongation of life or approximately 20 days. Animals were found in better health, with less signs of moribundity.

Fig. 41

20/22






Fig. 42



The results with this dosage are truly impressive. Survival was enhanced significantly. The three surviving animals sacrificed on day 60, each had a small tumor.

Fig. 43

21/22



Thus far, these are the most striking findings. Deaths at day 31 were minimal and prolongation of life was statistically significant. Moreover, at this dose survival rates at day 56 were significantly increased, with approximately 60% of animals alive and only four animals exhibiting visible tumors.

Fig. 44




Fig. 45

22/22

Combination of Doxorubicin and CoQ10 IV Formulation




Fig. 46




Fig. 47